Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO2011 Monotherapy or in Combination With Toripalimab in Advanced Solid Tumors
NCT06088004Phase 2Recruiting
- Sponsor
- Abogen Bioscience
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ABO2011 in solid tumor (2 arms), sponsored by Abogen Bioscience. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events at 90 days and 3 more. Started Sep 2023; status: recruiting.
02
Drugs
ABO2011
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06088004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06088004.